CagriSema vs Tirzepatide vs Retatrutide: Comparing the Next-Generation Metabolic Combinations

CagriSema vs tirzepatide vs retatrutide metabolic peptide comparison Durham Peptides Canada

These three compounds represent the cutting edge of metabolic peptide research — but they reach that frontier by two fundamentally different routes. CagriSema combines two separate molecules (an amylin analog plus a GLP-1 agonist). Tirzepatide and retatrutide are single molecules engineered to hit multiple receptors at once. Understanding that architectural difference — multi-molecule combination versus multi-target single molecule — is the key to understanding how these three relate and why a researcher might choose one over another.

This article compares all three from a research perspective. For the deep dives, see What Is CagriSema? and Triple Agonist Peptides Explained.

The Architectural Divide: One Molecule or Two?

The single most important distinction:

Multi-molecule combination (two peptides, one vial):

• CagriSema = cagrilintide (amylin analog) + semaglutide (GLP-1 agonist)

Multi-target single molecule (one peptide, multiple receptors):

• Tirzepatide = one molecule activating GLP-1 + GIP receptors (dual agonist)

• Retatrutide = one molecule activating GLP-1 + GIP + glucagon receptors (triple agonist)

So CagriSema is a blend; tirzepatide and retatrutide are engineered single molecules. They all pursue the same goal — engaging multiple metabolic pathways — through opposite design philosophies.

The Receptor Systems Compared

The other key difference is which pathways each engages. Notably, CagriSema is the only one of the three that brings in the amylin system — the others stay within the incretin/glucagon family.

Compound	Architecture	Receptor systems engaged	"Novel" pathway
CagriSema	Two molecules	Amylin/calcitonin + GLP-1	Amylin
Tirzepatide	Single molecule	GLP-1 + GIP	GIP
Retatrutide	Single molecule	GLP-1 + GIP + glucagon	Glucagon

All three include GLP-1 activation as a common foundation. What differs is the second (and third) pathway each adds: CagriSema adds amylin, tirzepatide adds GIP, retatrutide adds both GIP and glucagon.

Full Side-by-Side

Property	CagriSema	Tirzepatide	Retatrutide
Type	Two-molecule blend	Single dual agonist	Single triple agonist
Components	Cagrilintide + semaglutide	One molecule	One molecule
Receptors	Amylin + GLP-1	GLP-1 + GIP	GLP-1 + GIP + glucagon
Generation	Combination approach	Incretin gen 2	Incretin gen 3
Clinical stage	Phase 3 (REDEFINE / REIMAGINE)	Established	Advanced trials
Durham vial	10mg blend (C$145)	10mg (C$60)	10mg (C$120)

How the Design Philosophies Differ in Practice

CagriSema (combination): Pairing two separate, well-characterized molecules means each component's behavior is independently understood, and the ratio can in principle be studied by varying the components. The tradeoff is that you're managing two peptides (and, for purchasing, verifying two). It also uniquely brings the amylin pathway into play.

Tirzepatide and retatrutide (single molecule): A single engineered molecule that hits multiple receptors simplifies the formulation to one compound with one pharmacokinetic profile, and allows the balance of receptor activation to be tuned at the molecular-design level. The tradeoff is that the multi-receptor activity is locked into the molecule rather than adjustable by mixing.

Neither approach is universally "better" — they're different strategies, and the metabolic field is actively pursuing both in parallel. For the single-molecule progression from single to dual to triple agonism, see Triple Agonist Peptides Explained; for the dual-agonist story specifically, see Semaglutide vs Tirzepatide.

When a Researcher Would Choose Each

• Studying the amylin + GLP-1 combination, or multi-molecule combination design → CagriSema.

• Studying GLP-1 + GIP dual agonism in a single molecule → tirzepatide.

• Studying GLP-1 + GIP + glucagon triple agonism in a single molecule → retatrutide.

The choice is dictated by which receptor systems and which design architecture a research protocol is built around — not by a simple "most effective" ranking.

Quality Standards Across All Three

All three are Janoshik-verified to ≥99% purity with mass-spec identity confirmation (per component, for the CagriSema blend). Metabolic readouts are sensitive to material quality, so verification matters regardless of which compound a protocol uses. See How to Read a Janoshik COA and the Lab Results page.

Frequently Asked Questions

What's the difference between CagriSema and tirzepatide? CagriSema is a blend of two molecules (cagrilintide + semaglutide) engaging amylin and GLP-1; tirzepatide is a single engineered molecule engaging GLP-1 and GIP. Different architecture and different second pathway.

Is CagriSema better than retatrutide? They engage different receptor systems (amylin/GLP-1 versus GLP-1/GIP/glucagon) through different designs (blend versus single molecule). "Better" depends entirely on the research question; both are advanced compounds with substantial trial data.

Which one includes the amylin pathway? Only CagriSema — via its cagrilintide component. Tirzepatide and retatrutide stay within the incretin/glucagon family.

Are all three single molecules? No. Tirzepatide and retatrutide are single molecules; CagriSema is a two-molecule blend.

Which is newest? The single-molecule field has progressed to triple agonism (retatrutide). CagriSema represents the parallel combination-approach frontier, in advanced Phase 3 trials.

Are all three available in Canada? Yes — Durham Peptides stocks CagriSema, tirzepatide, and retatrutide.

Final Thoughts

CagriSema, tirzepatide, and retatrutide are three answers to the same question — how do you engage more than one metabolic pathway at once? — arrived at by two different design philosophies. CagriSema blends two molecules and uniquely brings in the amylin system; tirzepatide and retatrutide engineer single molecules to hit two and three incretin/glucagon receptors respectively. For researchers, the choice comes down to which receptor systems and which architecture the protocol requires.

For the CagriSema deep dive, see What Is CagriSema?; for the single-molecule multi-agonist story, see Triple Agonist Peptides Explained. Browse the metabolic category at durhampeptides.ca/category/metabolic-research-peptides.

Selected Research References

1. Garvey WT, Blüher M, Kushner RF, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/40548661/

2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/

3. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/

4. Frías JP, Deenadayalan S, Erichsen L, et al. Efficacy and Safety of Co-administered Once-Weekly Cagrilintide and Semaglutide in Adults with Type 2 Diabetes. The Lancet. 2023;402(10403):720-730. https://pubmed.ncbi.nlm.nih.gov/37364590/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.